Clinical trials: Motor Neuron Diseases, open to volunteers
Spinal Cord Injury, Safety
Safety and Early Efficacy of iPSC-Derived Motor Neuron Progenitor Cells (XS228) in Subacute Spinal Cord Injury: A Phase I Trial
This Phase I clinical trial is designed to evaluate the safety, tolerability of XS228 ( iPSC-Derived Motor Neuron Progenitor Cells) in patients with Subacute Spinal Cord Injury
- Conditions
- Spinal Cord Injury, Safety, Clinical Trials, Efficacy
- Trial name
- NCT06976229
- Testing
- Allogeneic Human Induced Pluripotent Stem Cell (iPSC)-Derived Motor Neuron Progenitor Cells
- Where
- China
- Volunteers
- 12 people
- Sponsor
- XellSmart Bio-Pharmaceutical (Suzhou) Co., Ltd.
Tetraplegia, Locked-in Syndrome
Investigation on the Cortical Communication (CortiCom) System
The CortiCom system consists of 510(k)-cleared components: platinum PMT subdural cortical electrode grids, a Blackrock Microsystems patient pedestal, and an external NeuroPort Neural Signal Processor.
- Conditions
- Tetraplegia, Locked-in Syndrome, Brainstem Stroke, Amyotrophic Lateral Sclerosis
- Trial name
- CortiCom (NCT03567213)
- Testing
- Surgical implantation of CortiCom system
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Johns Hopkins University
Amyotrophic Lateral Sclerosis
Neural Stem Cell Treatment for Amyotrophic Lateral Sclerosis (STEMALS)
A Not for Profit Phase II Study to Evaluate Safety, Efficacy and Biomarkers secondary endpoints of Human Neural Stem cell intracerebroventricular transplantation in amyotrophic lateral sclerosis patients: a randomized, placebo…
- Trial name
- STEMALS (NCT06344260)
- Testing
- human Neural Stem Cells (hNSC)
- Where
- 4 sites in Italy
- Volunteers
- 30 people
- Sponsor
- Casa Sollievo della Sofferenza IRCCS
ALS (Amyotrophic Lateral Sclerosis)
Safety and Tolerability Study of CTx1000 In Participants With Amyotrophic Lateral Sclerosis
This clinical study is in participants with Amyotrophic Lateral Sclerosis and is designed to evaluate the safety and tolerability of the gene therapy CTx1000.
- Trial name
- KOANEWA (NCT07401121)
- Testing
- AAV9 Gene therapy
- Where
- Australia
- Volunteers
- 15 people
- Sponsor
- Celosia Therapeutics Pty Ltd
Amyotrophic Lateral Sclerosis, ENGRAILED1
Identifying Biomarkers in ALS Patients Using Neuronal Derived Extracellular Vesicles
Rationale. ENGRAILED1 (EN1) is under consideration as a therapeutic approach for amyotrophic lateral sclerosis (ALS). To assess EN1 target engagement in patients, we aim to identify EN1-responsive biomarkers suitable as…
- Trial name
- BALNEV (NCT07334743)
- Where
- France
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Fondation Ophtalmologique Adolphe de Rothschild
Neurologic Disorders, Nervous System Diseases
Neurologic Stem Cell Treatment Study
This is a human clinical study involving the isolation of autologous bone marrow derived stem cells (BMSC) and transfer to the vascular system and inferior 1/3 of the nasal passages in order to determine if such a treatment will…
- Conditions
- Neurologic Disorders, Nervous System Diseases, Neurodegenerative Diseases, Neurological Disorders
- Trial name
- NEST (NCT02795052)
- Testing
- Intravenous and Intranasal BMSC
- Where
- 3 sites in United States, United Arab Emirates
- Volunteers
- 500 people
- Sponsor
- MD Stem Cells
Amyotrophic Lateral Sclerosis (ALS)
Usnoflast Neuromuscular Investigation for Treatment Efficacy in Amyotrophic Lateral Sclerosis
Usnoflast Neuromuscular Investigation for Treatment Efficacy in Amyotrophic Lateral Sclerosis
- Trial name
- UNITE-ALS (NCT07023835)
- Testing
- 50 mg Usnoflast, 75 mg Usnoflast
- Where
- 49 sites in United States, Australia and 10 more
- Volunteers
- 240 people
- Sponsor
- Zydus Therapeutics Inc.
Hereditary Spastic Paraplegia, Primary Lateral Sclerosis
Spastic Paraplegia - Centers of Excellence Research Network
The Spastic Paraplegia - Centers of Excellence Research Network (SP-CERN) is a collaborative research consortium dedicated to advancing the understanding, diagnosis, and treatment of hereditary spastic paraplegia (HSP) and…
- Conditions
- Hereditary Spastic Paraplegia, Primary Lateral Sclerosis, SPG4, SPG5A
- Trial name
- SP-CERN (NCT06553976)
- Where
- 11 sites in United States
- Volunteers
- 100 people
- Sponsor
- Boston Children's Hospital
Amyotrophic Lateral Sclerosis
Analysis of Human ALS Tissues and Registry of ALS Patients
Amyotrophic Lateral Sclerosis (ALS), often referred to as Lou Gehrig's Disease, is a progressive, terminal condition of muscle weakness that is associated with degeneration of neurons in the spinal cord and brain.
- Trial name
- NCT05067179
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- University of Illinois Chicago
Amyotrophic Lateral Sclerosis (ALS)
A Clinical Trial to Evaluate NB-4746 in Participants With Amyotrophic Lateral Sclerosis.
The purpose of this trial is to learn about the effects of NB-4746 compared with placebo in people with amyotrophic lateral sclerosis.
- Trial name
- NCT07369076
- Testing
- NB-4746 High dose, NB-4746 Low dose, NB-4746 (Dose TBD)
- Where
- 12 sites in Australia, Canada and 2 more
- Volunteers
- 80 people
- Sponsor
- Nura Bio
Amyotrophic Lateral Sclerosis & Other Neuromuscular Disorders
Using Gaze to Enable Head-neck Movements in Patients With Head Drop
The investigators will develop and evaluate controllers for a powered neck exoskeleton in patients with amyotrophic lateral sclerosis (ALS) to understand how to allow adequate personalization and function and achieves…
- Trial name
- NCT07836751
- Testing
- neck exoskeleton controller
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- University of Utah
Spinal Muscular Atrophy Type 3
Evaluation of Safety and Efficacy of Gene Therapy Drug in the Treatment of Spinal Muscular Atrophy (SMA) Type 3 Patients
The study will evaluate safety and efficacy of intrathecal delivery of GC101 gene therapy drug as a treatment of spinal muscular atrophy Type 3 (SMA 3) patients.
- Trial name
- NCT06421831
- Testing
- GC101
- Where
- China
- Volunteers
- 21 people
- Sponsor
- GeneCradle Inc
Amyotrophic Lateral Sclerosis (ALS)
Clinical Study of Regulatory T Cells (Tregs) in the Treatment of Neurodegenerative Diseases
An open, multi- center phase Ⅰ clinical study evaluating the safety and efficacy of autologous human polyclonal regulatory T cell injection (NP001 cell injection) in patients with Neurodegenerative diseases (ALS).
- Trial name
- NCT06671236
- Testing
- Autologous Human Polyclonal Regulatory T Cells Injection (NP001 Cell Injection)
- Where
- China
- Volunteers
- 12 people
- Sponsor
- Novabio Therapeutics
Spinal Muscular Atrophy, SMA
A Study to Evaluate How Apitegromab Works in Subjects Who Are Less Than 2 Years Old and Have Spinal Muscular Atrophy
This double-blind, Phase 2, multiple-dose study will be conducted to evaluate the PK/PD, efficacy, safety, and tolerability of apitegromab in subjects <2 years old with 5q autosomal recessive SMA who have delayed motor milestones…
- Conditions
- Spinal Muscular Atrophy, SMA, Spinal Muscular Atrophy Type 2, Spinal Muscular Atrophy Type 3
- Trial name
- OPAL (NCT07047144)
- Testing
- Apitegromab, Nusinersen, Risdiplam
- Where
- 23 sites in United States, Belgium and 5 more
- Volunteers
- 52 people
- Sponsor
- Scholar Rock, Inc.
Stroke, Parkinson Disease (PD)
Digital Patient Engagement in Technology-Supported Neurorehabilitation
The goal of this observational study is to investigate digital patient engagement and its psychosocial correlates and potential predictors among adults aged 18-85 years with neurological disorders who are undergoing…
- Conditions
- Stroke, Parkinson Disease (PD), Motor Neuron Disease, Spinal Cord Injury
- Trial name
- PSY-NeT-Engage (NCT07794072)
- Where
- 3 sites in Italy
- Volunteers
- 129 people
- Sponsor
- Catholic University, Italy
Amyotrophic Lateral Sclerosis (ALS)
The Safety, Tolerability and Preliminary Efficacy of Derived Motor Neuron Progenitor Cells (XS228CN) in Subjects With Amyotrophic Lateral Sclerosis
A Phase I Study to Assess the Safety, Tolerability and Preliminary Efficacy of Derived Motor Neuron Progenitor Cells (XS228CN) in Subjects with Amyotrophic Lateral Sclerosis
- Trial name
- NCT07118319
- Testing
- Human Allogeneic Induced Pluripotent Stem Cells (iPSCs) -Derived Motor Neuron Progenitor Cells (XS228CN)
- Where
- China
- Volunteers
- 12 people
- Sponsor
- XellSmart Bio-Pharmaceutical (Suzhou) Co., Ltd.
Paralysis; Quadriplegic, Quadraplegia
MindEx: A Novel, Multifocal, Cognitive Brain-Machine Interface System
This research study is being done to develop a novel brain-computer interface (BCI) technology that can enable severely paralyzed individuals to interact with the world through direct brain-control of a computer.
- Conditions
- Paralysis; Quadriplegic, Quadraplegia, Tetraplegia, Tetraplegic Motor Dysfunction Following Brainstem or Spinal Cord Injury
- Trial name
- NCT05936619
- Testing
- Mind Extender (MindEx)
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Nader Pouratian
Amyotrophic Lateral Sclerosis ALS7
The Importance of Positive Expiratory Pressure Associated With the In-exsufflator in ALS Patients
Amyotrophic Lateral Sclerosis (ALS) is a fatal neurodegenerative disorder that impairs motor neurons, with a life expectancy of 2 to 7 years after diagnosis.
- Trial name
- PEPINEX (NCT06249412)
- Testing
- MI-E with PEP function activated during the pause, MI-E without PEP function activated during the pause
- Where
- France
- Volunteers
- 11 people
- Sponsor
- Groupe Hospitalier du Havre
Anarthria, Dysarthria
Feasibility of the BrainGate2 Neural Interface System in Persons With Tetraplegia
The purpose of this study is to obtain preliminary device safety information and demonstrate proof of principle (feasibility) of the ability of people with tetraplegia to control a computer cursor and other assistive devices with…
- Conditions
- Anarthria, Dysarthria, Tetraplegia, Spinal Cord Injuries
- Trial name
- BG-Speech-01 (NCT05724173)
- Testing
- BrainGate Neural Interface System
- Where
- 2 sites in United States
- Volunteers
- 3 people
- Sponsor
- Leigh R. Hochberg, MD, PhD.
Multiple Sclerosis, Amyotrophic Lateral Sclerosis
Polish Version Fatigue Severity Scale
Fatigue is one of main symptoms in multiple sclerosis, amyotrophic lateral sclerosis and other diseases with profound effect on quality of life and professional and social functioning.
- Conditions
- Multiple Sclerosis, Amyotrophic Lateral Sclerosis, Stroke, Ischemic
- Trial name
- NCT06668649
- Testing
- Testing with Questionnaires
- Where
- 2 sites in Poland
- Volunteers
- 310 people, healthy volunteers welcome
- Sponsor
- Jakub Antczak